CDC’s “Activity Levels” turn community respiratory-virus surveillance into five labels (Very Low → Very High). Here’s how to interpret the signals—wastewater, emergency department/ARI activity, and severe-illness context—and what families, schools, and workplaces can do next without panic.
If your family used Nara Organics Whole Milk Organic Powdered Infant Formula, the FDA says stop using it now. Know the warning signs of infant botulism, preserve lot/use-by info, and get emergency care right away if symptoms appear.
If you may have been exposed to Andes virus through the 2026 U.S. cruise-ship outbreak and you develop fever or breathing symptoms, contact a clinician and public health promptly. CDC and WHO interim guidance explains the monitoring window after exposure, common symptom patterns, and how labs use coordinated testing—when different tests are most useful.
On July 1, 2026, the FDA expanded Casgevy (exagamglogene autotemcel) so some children age 2 and older with sickle cell disease (SCD) can be evaluated for the gene-edited, stem-cell therapy—previously approved for older children. Here’s what the FDA change does and does not mean, what benefits were seen in pediatric data, and what risks and long-term monitoring families should discuss.
CMS’s June 2026 Hospital Price Transparency FAQs update what hospitals must post online (including machine-readable expectations) and how consumers can use CMS’s enforcement-actions page. Here’s how to interpret what you find—and why those posted “prices/charges” may still not equal what you’ll personally pay with insurance.
On June 10, 2026, the FDA approved label updates for OTC alli (orlistat) 60 mg that add clearer warnings about rare but serious kidney risks, including kidney stones. If you have a history of kidney disease or kidney stones, the label advises asking a health care provider before using alli—and stopping alli and seeking medical guidance promptly if symptoms appear.
CDC’s national wastewater dashboard updates every Friday. Learn what “wastewater viral activity” means, what it can’t tell you about individuals, and how families can use the signal to plan everyday prevention and keep vaccines up to date.
Seeing an FDA recall record for an implanted deep brain stimulation (DBS) neurostimulator can be alarming. Here’s what the specific FDA record for Medtronic Kinetra model 7428 describes, how to check your device identifiers, and when symptom changes should trigger urgent care.
ACOG’s pregnancy vaccine schedule and CDC’s vaccine-table view can look mismatched at first glance—especially for COVID-19. Here’s how to use ACOG for the “what to plan,” then use CDC’s dedicated pregnancy pages to confirm the timing logic for RSV (Abrysvo) and COVID-19.
FDA updated its AI-Enabled Medical Devices list on June 16, 2026. Here’s how patients, caregivers, and clinician-adjacent readers can check whether an AI-enabled medical device is FDA-authorized—and what the list and linked FDA entries do (and don’t) tell you.
In 2026, the American Cancer Society labeled blood-based colorectal cancer screening tests as “not preferred.” Here’s what that means for everyday decisions—what to ask if a clinic offers a blood test, and why a positive result still requires timely colonoscopy follow-up.
A July 8, 2026 CASTL trial tests how to deliver smoking-cessation components during lung cancer screening visits—using cost-and-effectiveness “value” to find approaches that are practical to scale in real-world programs.
A USDA final rule effective June 8, 2026 expands which “fluid milk” options participating schools and child care sites can offer. If you’re seeing whole milk or 2% milk on your child’s menu in summer 2026, here’s how to understand the change—and what to do if your child needs a lactose-free option or has a milk allergy.
After a measles exposure at daycare/school, timing matters. MMR works best within 72 hours of the first exposure. Immune globulin may be an option within 6 days for people who can’t safely get MMR—so call a clinician and follow local public health instructions right away.
Medicare’s time-limited “GLP-1 Bridge” starts July 1, 2026. If you’re enrolled in an eligible Medicare Part D plan type and meet CMS’s age/BMI and health-condition criteria, your clinician can request prior authorization for certain FDA-approved GLP-1 weight-loss drugs—with a $50 copay per month through Dec. 31, 2027.
CMS’s June 1, 2026 interim final rule creates a Medicaid eligibility condition for certain non-pregnant adults to meet an 80-hours-per-month “community engagement” standard (or another qualifying basis). The rule also requires states to verify compliance and give enrollees a 30-calendar-day response window if they can’t verify.
If your area shows an “A(H5) detected” wastewater result, it’s a community monitoring signal—not proof that anyone in your household is infected. Learn what the dashboard can and can’t tell you, and when symptoms after relevant exposure should prompt medical evaluation.
If you call or text 988 and your local crisis option can’t take your contact, the system is designed to route you to a national backup. Wait times can still vary by call/text/chat method and local demand—so if one path doesn’t connect, trying another 988 method can help you reach a counselor faster.
New HRSA-backed U.S. cervical cancer screening guidance adds a patient-collected (at-home) option for high-risk HPV testing for average-risk adults ages 30 to 65. The preferred screening interval is every 5 years, and abnormal results may require additional follow-up tests to complete screening.
CMS’s proposed CY 2027 Hospital OPPS/ASC rule would adjust Medicare hospital outpatient payments for certain 340B-acquired drugs, change how some outpatient imaging is paid (including rural Sole Community Hospital exemptions), and continue the phase-out of the Inpatient Only (IPO) list. CMS also issued an RFI to improve hospital price-transparency data. The proposal is not final; comments are due August 31, 2026.
On June 10, 2026, FDA approved updates to the OTC weight-loss drug alli (orlistat 60 mg) label to highlight a rare risk of acute kidney injury and kidney stones. The label advises people who have ever had kidney disease or kidney stones to ask a health care provider first, and to stop using alli and contact a doctor if specific kidney-related symptoms appear.
If you may have been exposed to mpox, JYNNEOS post-exposure prophylaxis works best when started within 4 days (and may still help if given up to 14 days). If you develop a new, unusual rash after a relevant exposure window, contact a clinician promptly to ask about mpox PCR testing.
End of content
End of content
